^
Association details:
| Biomarker: | ER positive + ESR1 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | camizestrant (AZD9833) (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Clinical activity of camizestrant, a next-generation SERD, versus fulvestrant in patients with a detectable ESR1 mutation: Exploratory analysis of the SERENA-2 phase 2 trial.
Published date:
05/25/2023
Excerpt:
...post-menopausal women with advanced ER+, HER2˗ breast cancer with disease recurrence or progression after ≤1 endocrine therapy in the advanced setting in the Phase 2 randomized SERENA-2 study...Camizestrant showed improved outcome vs F in patients with a detectable ESR1m at baseline and in the subgroups tested. The greatest median PFS improvement was seen in patients where a single ESR1m variant was detected, suggesting that early intervention upon detection of an ESR1m may provide the maximum patient benefit for camizestrant...
DOI:
10.1200/JCO.2023.41.16_suppl.1066
Trial ID:
